Release Date
Geography
Language of Resource
Full Text Available
Open Access / OK to Reproduce
Peer Reviewed
Objective
Among recipients of opioid agonist therapy (OAT) in Ontario, Canada, early in the COVID-19 pandemic, was there an association between dispensing of increased take-home doses and treatment retention or opioid-related harm?
Findings/Key points
In Ontario, Canada, during the COVID-19 pandemic, dispensing of increased take-home doses of OAT was significantly associated with lower rates of treatment interruption and discontinuation among some subsets of patients, and there were no statistically significant increases in opioid-related overdoses, although the findings may be susceptible to residual confounding and should be interpreted cautiously.
Design/methods
Retrospective propensity-weighted cohort study of 21 297 OAT recipients